Precision BioSciences, Inc. Common Stock (DTIL) Stock
Fundamentals
Recent news

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
DTIL

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
DTIL

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
DTIL

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
DTIL
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
DTIL

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
DTIL

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
DTIL

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
DTIL

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
DTIL

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DTIL

Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
DTIL

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
DTIL

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
DTIL

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
DTIL
About Precision BioSciences, Inc. Common Stock
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Amoroso | President, CEO & Director | 1978 |
| Mr. John Alexander Kelly R.Ph. | Chief Operating Officer | 1967 |
| Mr. Dario Scimeca J.D. | Chief Legal Officer & Secretary | 1975 |
| Dr. Jefferson J. Smith Ph.D. | Co-Founder & Chief Research Officer | 1973 |
| Mr. Naresh Tanna | Chief Financial Officer | 1981 |
| Ms. Mei Burris | VP of Finance & Chief Accounting Officer | 1986 |
| Dr. Cassie Gorsuch Ph.D. | Chief Scientific Officer | — |
| Ms. Juli Blanche | Chief People Officer | — |
| Ms. Cindy Atwell | Chief Development Officer | — |
| Mr. Neil Leatherbury M.S. | Senior VP and Head of Chemistry, Manufacturing & Controls | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +16.6 | -11.3 | +8.2 | -18.6 |



